Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 12
2020 19
2021 23
2022 22
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Lymphatic vessels in the age of cancer immunotherapy.
Karakousi T, Mudianto T, Lund AW. Karakousi T, et al. Nat Rev Cancer. 2024 Apr 11. doi: 10.1038/s41568-024-00681-y. Online ahead of print. Nat Rev Cancer. 2024. PMID: 38605228 Review.
Structural basis for self-discrimination by neoantigen-specific TCRs.
Finnigan JP, Newman JH, Patskovsky Y, Patskovska L, Ishizuka AS, Lynn GM, Seder RA, Krogsgaard M, Bhardwaj N. Finnigan JP, et al. Nat Commun. 2024 Mar 8;15(1):2140. doi: 10.1038/s41467-024-46367-9. Nat Commun. 2024. PMID: 38459027 Free PMC article.
Tumor-Intrinsic Galectin-3 Suppresses Melanoma Metastasis.
Mohammed NBB, Lau LS, Souchak J, Qiu S, Ahluwalia MS, Osman I, Dimitroff CJ. Mohammed NBB, et al. J Invest Dermatol. 2024 Mar 6:S0022-202X(24)00169-6. doi: 10.1016/j.jid.2024.02.011. Online ahead of print. J Invest Dermatol. 2024. PMID: 38458429
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Jacques SK, et al. Eur J Cancer. 2024 Mar;199:113563. doi: 10.1016/j.ejca.2024.113563. Epub 2024 Jan 22. Eur J Cancer. 2024. PMID: 38278007
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
92 results